

## Connecting via Winsock to STN

2/25/05

10/635,040a

Welcome to STN International! Enter x:x

## Structure Search

LOGINID: SSSPTAAJP1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2  
H00C  
nA/L(6-9)

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within  
STN Express with DiscoverG!>0  
NEWS 4 OCT 28 KOREPAT now available on STN  
NEWS 5 NOV 30 PHAR reloaded with additional data  
NEWS 6 DEC 01 LISA now available on STN  
NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004  
NEWS 8 DEC 15 MEDLINE update schedule for December 2004  
NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness  
alerts (SDIs) affected.  
NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness  
alerts (SDIs) affected  
NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness  
alerts (SDIs) affected  
NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness  
alerts (SDIs) affected  
NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB  
NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN  
NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED  
NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and  
February 2005  
NEWS 17 FEB 25 CA/CAPLUS - Russian Agency for Patents and Trademarks  
(ROSPATENT) added to list of core patent offices covered  
NEWS 18 FEB 10 STN Patent Forums to be held in March 2005  
NEWS 19 FEB 16 STN User Update to be held in conjunction with the 229th AC  
National Meeting on March 13, 2005

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

**NEWS HOURS STN Operating Hours Plus Help Desk Availability**

NEWS INTER General Internet Information

NEWS LOGIN      Welcome Banner and News Items

**NEWS PHONE Direct Dial and Telecommunication Network Access to STN**

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 14:01:01 ON 25 FEB 2005

FILE 'REGISTRY' ENTERED AT 14:01:09 ON 25 FEB 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 FEB 2005 HIGHEST RN 836595-43-8  
DICTIONARY FILE UPDATES: 23 FEB 2005 HIGHEST RN 836595-43-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

⇒

Uploading C:\Program Files\Stnexp\Queries\10635040a.str



```

chain nodes :
10 11 12 13 14 15 16 17
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-10 3-15 9-16 10-12 11-12 12-13 14-15 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-10 5-7 6-9 7-8 8-9 9-16 10-12 11-12


```

exact bonds :  
3-15 12-13 14-15 16-17  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6

Hydrogen count :  
10:= exact 1  
Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L1  
SAMPLE SEARCH INITIATED 14:01:29 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 2 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 8 TO 329  
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 full  
FULL SEARCH INITIATED 14:01:34 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 108 TO ITERATE

100.0% PROCESSED 108 ITERATIONS  
SEARCH TIME: 00.00.01

39 ANSWERS

L3 39 SEA SSS FUL L1

=> fil caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
161.33 161.54

FILE 'CAPLUS' ENTERED AT 14:01:39 ON 25 FEB 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Feb 2005 VOL 142 ISS 10  
FILE LAST UPDATED: 24 Feb 2005 (20050224/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L3  
L4 9 L3

=> d L4 iib abs hitstr 1-9  
'IIB' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AI, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data  
DALL ----- ALL, delimited (end of each field identified)  
DMAX ----- MAX, delimited for post-processing  
FAM ----- AN, PI and PRAI in table, plus Patent Family data  
FBIB ----- AN, BIB, plus Patent FAM  
IND ----- Indexing data  
IPC ----- International Patent Classifications  
MAX ----- ALL, plus Patent FAM, RE  
PATS ----- PI, SO  
SAM ----- CC, SX, TI, ST, IT  
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
SCAN must be entered on the same line as the DISPLAY,  
e.g., D SCAN or DISPLAY SCAN)  
STD ----- BIB, IPC, and NCL  
  
IABS ----- ABS, indented with text labels  
IALL ----- ALL, indented with text labels

IBIB ----- BIB, indented with text labels  
IMAX ----- MAX, indented with text labels  
ISTD ----- STD, indented with text labels  
  
OBIB ----- AN, plus Bibliographic Data (original)  
OIBIB ----- OBIB, indented with text labels  
  
SBIB ----- BIB, no citations  
SIBIB ----- IBIB, no citations  
  
HIT ----- Fields containing hit terms  
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
                      containing hit terms  
HITRN ----- HIT RN and its text modification  
HITSTR ----- HIT RN, its text modification, its CA index name, and  
                      its structure diagram  
HITSEQ ----- HIT RN, its text modification, its CA index name, its  
                      structure diagram, plus NTE and SEQ fields  
FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
                      its structure diagram  
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
                      structure diagram, plus NTE and SEQ fields  
KWIC ----- Hit term plus 20 words on either side  
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BTB):end

=> d 14 ibib abs hitstr 1-9

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2004:80529 CAPLUS  
DOCUMENT NUMBER: 140:133861  
TITLE: ADP antagonists and ACAT inhibitors for treating  
arteriosclerosis  
INVENTOR(S): Asai, Fumitoshi; Inaba, Toshimori; Ogawa, Taketoshi  
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan  
SOURCE: PCT Int. Appl., 29 pp.  
CODEN: PIIXD2  
CO-PE  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009119	A1	20040129	WO 2003-JP9108	20030717
W: AE, AG, AL, CO, CR, CU, GM, HR, HU, LS, LT, LU, PG, PH, PL, TR, TT, TZ, RW: GH, GM, KE,	AM, AT, AU, AZ, CZ, DE, DK, DM, ID, IL, IN, IS, LV, MA, MD, MG, RO, RU, SC, UA, UG, US, UZ, LS, MW, MZ, SD,	BA, BB, BG, BR, BY, BZ, DZ, EC, EE, ES, FI, JP, KE, KG, KP, KR, MK, MN, MW, MX, MZ, SD, SE, SG, SK, SL, VC, VN, YU, ZA, ZM, SL, SZ, TZ, UG, ZM,	CA, CH, CN, GB, GD, GE, GH, KZ, LC, LK, LR, NI, NO, NZ, OM, SY, TJ, TM, TN, ZW AM, AZ, BY,	

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2004051639 A2 20040219 JP 2003-275276 20030716

PRIORITY APPLN. INFO.: JP 2002-209165 A 20020718

AB A medicinal composition characterized in that an ADP receptor antagonist and an ACAT inhibitor, are administered either simultaneously or sep. at a definite interval. The medicinal composition is useful as a preventive or a remedy for arteriosclerosis or diseases derived from arteriosclerosis, such as ischemic heart disease, ischemic brain disease, and peripheral circulation failure in warm-blooded animals (in particular, humans). For example, pharmacol. activities of 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (I) and N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfuric acid salt (II) were studied using rabbits and tablets containing I 10 mg and II 30 mg each were formulated.


IT 189198-30-9 189198-32-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ADP antagonists and ACAT inhibitors for treatment of arteriosclerosis and related disorders thereof)

RN 189198-30-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-32-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 189198-30-9

CMF C25 H40 N2 O3



CM 2



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003:818314 CAPLUS  
DOCUMENT NUMBER: 139:297051  
TITLE: Medicinal composition comprising ACAT inhibitor and insulin resistance improving agent  
INVENTOR(S): Inaba, Toshimori; Fujiwara, Toshihiko  
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan  
SOURCE: PCT Int. Appl., 29 pp.  
CQDEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION: *ODP*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084572	A1	20031016	WO 2003-JP4296	20030403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2481379	AA	20031016	CA 2003-2481379	20030403
BR 2003008871	A	20050104	BR 2003-8871	20030403
EP 1493448	A1	20050105	EP 2003-745697	20030403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2004002365	A2	20040108	JP 2003-101076	20030404
PRIORITY APPLN. INFO.:			JP 2002-103134	A 20020405
			WO 2003-JP4296	W 20030403


AB It is intended to provide a medicinal composition for preventing or treating arteriosclerosis or diseases caused by arteriosclerosis which comprises an ACAT inhibitor and an insulin resistance improving agent. For example, tablets were formulated containing 5-[(4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]phenyl)methyl]-2,4-thiazolidinedione hydrochloride 50, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide hemisulfate 10, lactose 113, starch 25, and Mg stearate 2 mg/tablet.

IT 189198-30-9 608510-47-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(medicinal composition comprising ACAT inhibitor and insulin resistance improving agent)

RN 189198-30-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 608510-47-0 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9


CMF C25 H40 N2 O3



CM 2

CRN 7664-93-9

CMF H2 O4 S



REFERENCE COUNT:

40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:202511 CAPLUS

DOCUMENT NUMBER: 138:226765

TITLE: Medicinal compositions containing angiotensin II receptor antagonists

INVENTOR(S): Sada, Toshio; Inaba, Toshimori

PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan

SOURCE: PCT Int. Appl., 26 pp.

ODP

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

ODP

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020315	A1	20030313	WO 2002-JP8629	20020827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2003146907	A2	20030521	JP 2002-246112	20020827
EP 1421953	A1	20040526	EP 2002-762874	20020827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012254	A	20041019	BR 2002-12254	20020827
US 2004198788	A1	20041007	US 2004-789340	20040226
PRIORITY APPN. INFO.:			JP 2001-257435	A 20010828
			WO 2002-JP8629	W 20020827


AB Disclosed are medicinal compns. for administering an angiotensin II receptor antagonist and an ACAT inhibitor either at the same time or sep. at a certain interval. The compns. are effective for the prevention and treatment of arteriosclerosis and cardiac ischemia. For example, tablets were formulated containing olmesartan 50, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide 10, lactose 113, starch 25, and Mg stearate 2 mg/each.

IT 189198-30-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(medicinal compns. containing angiotensin II receptor antagonist and ACAT inhibitor)

RN 189198-30-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:792270 CAPLUS


DOCUMENT NUMBER: 137:310809

TITLE: Preparation of indolines as intermediates for preparation of ACAT inhibitors  
 INVENTOR(S): Tanabe, Hideo; Oyama, Yuzuru; Kiyota, Hiroshi  
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002302481	A2	20021018	JP 2002-24876 JP 2001-26375	20020201 20010202
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S): MARPAT	137:310809			
GI				

(ours is 2001-26374 =)

ODP



Yes



Yes

AB The compds. I (R<sub>1</sub>, R<sub>2</sub> = lower alkyl; R<sub>3</sub> = octyl) or their salts are prepared by deprotection of I (R<sub>1</sub>, R<sub>2</sub> = lower alkyl; R<sub>3</sub> = amino-protecting group) or their salts and octylation of I (R<sub>1</sub>, R<sub>2</sub> = lower alkyl; R<sub>3</sub> = H) or their salts. Carboxyindolines II (R<sub>1</sub>, R<sub>2</sub> = lower alkyl) are prepared from I (R<sub>1</sub>, R<sub>2</sub> = lower alkyl; R<sub>3</sub> = octyl). N-(1-acetyl-5-cyanomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide was reacted with NaOMe in MeOH under reflux for 6 h, alkylated with octyl bromide in the presence of (iso-Pr)<sub>2</sub>NET in xylene under reflux for 12 h, hydrolyzed in the presence of aqueous NaOH in PrOH under reflux for 15 h, and treated with H<sub>2</sub>SO<sub>4</sub> in acetone-H<sub>2</sub>O mixture to give 83% N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate.


IT 189198-32-1P  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indolines as intermediates for preparation of ACAT inhibitors)

RN 189198-32-1 CAPLUS  
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 189198-30-9  
CMF C25 H40 N2 O3



CM 2


CRN 7664-93-9  
CMF H2 O4 S



L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2002:716126 CAPLUS  
DOCUMENT NUMBER: 137:252985  
TITLE: Medicinal compositions containing bile acid transporter inhibitor and cholesterol acyltransferase inhibitors  
INVENTOR(S): Inaba, Toshimori  
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan  
SOURCE: PCT Int. Appl., 70 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072147	A1	20020919	WO 2002-JP2311	20020312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,			08/

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 JP 2002338496 A2 20021127 JP 2002-67841 20020313  
 PRIORITY APPLN. INFO.: JP 2001-72050 A 20010314  
 AB Disclosed are medicinal compns. for administering an ileal bile acid transporter inhibitor and a cholesterol acyltransferase (ACAT) inhibitor either at the same time or sep. at a certain interval. The effect of oral administration of both 4-[3-[(1-(3,5-difluorophenyl)ethylamino)-(4-methoxyphenyl)methyl]phenylamino]-3-hydroxy-3-cyclobutene-1,2-dione (I) and N-(1-octyl-5-carboxymethyl-4,6-dimethylindoline-7-yl)-2,2-dimethylpropaneamide (II) on blood serum triglyceride was prepared. Also, a tablet containing I 50, II 30, lactose 368, corn starch 50, magnesium stearate 2 mg was prepared  
 IT 189198-30-9  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hypolipemic compns. containing bile acid transporter inhibitor and cholesterol acyltransferase inhibitors)  
 RN 189198-30-9 CAPLUS  
 CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2002:615568 CAPLUS  
 DOCUMENT NUMBER: 137:169415  
 TITLE: Preparation of indoline derivatives as acyl-coenzyme A:cholesterol acyltransferase inhibitors  
 INVENTOR(S): Tomori, Hiroshi; Miyamoto, Hiroshi; Fukuhara, Hiroshi; Sonobe, Ryuichi; Miura, Motoko; Shimura, Kazuhiko; Fujimoto, Katsuhiko; Wakayama, Masakazu  
 PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan  
 SOURCE: PCT Int. Appl., 67 pp.  
 CODEN: PIXXD2



DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062758	A1	20020815	WO 2002-JP804	20020201
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2437134	AA	20020815	CA 2002-2437134	20020201
JP 2002302482	A2	20021018	JP 2002-24877	20020201

EP 1364942	A1	20031126	EP 2002-710441	20020201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2004058979	A1	20040325	US 2003-635040	20030731
NO 2003003432	A	20031001	NO 2003-3432	20030801
PRIORITY APPLN. INFO.:				
JP 2001-26374 A 20010202				
WO 2002-JP804 W 20020201				
OTHER SOURCE(S):		CASREACT 137:169415; MARPAT 137:169415		
GI				



our app

AB Novel intermediates such as I and II useful for synthesizing an indoline derivative having excellent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitory activity are prepared (R1 = an amino-protecting group; R2 and R3 = lower alkyl; and R4 = H or a carboxy-protecting group). Reaction of 1-acetyl-4,6-dimethylindoline with glyoxylic acid, hydrogenolysis with Pd-C and esterification with saturated HCl-EtOH solution, followed by nitration, hydrogenation, reaction with pivaloyl chloride, deacetylation, reaction with octyl bromide and base hydrolysis gave N-(5-carboxymethyl-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide sulfuric acid salt.

IT **189198-32-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(indoline derivative useful for ACAT inhibitor and their preparation)


RN 189198-32-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9


CMF C25 H40 N2 O3



CM 2

CRN 7664-93-9

CMF H2 O4 S



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:184896 CAPLUS

DOCUMENT NUMBER: 136:236854

TITLE: Medicinal compositions for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and HMG-CoA reductase inhibitors

INVENTOR(S): Kohama, Takafumi; Inaba, Toshimori

PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020009	A1	20020314	WO 2001-JP7438	20010829
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, SG, SK, US, ZA			W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, SG, SK, US, ZA	
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR			RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR	
AU 2001082541	A5	20020322	AU 2001-82541	20010829
CA 2420951	AA	20030228	CA 2001-2420951	20010829
EP 1314423	A1	20030528	EP 2001-961177	20010829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR			R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR	
NZ 524406	A	20040625	NZ 2001-524406	20010829
BR 2001013523	A	20040629	BR 2001-13523	20010829
RU-2246302	C2	20050220	RU 2003-105835	20010829
US 2002055533	A1	20020509	US 2001-943712	20010831
JP 2002145774	A2	20020522	JP 2001-262600	20010831
ZA 2003001543	A	20040609	ZA 2003-1543	20030225
NO 2003000946	A	20030408	NO 2003-946	20030228
US 2004092571	A1	20040513	US 2003-702930	20031105
PRIORITY APPLN. INFO.:			JP 2000-265082	A 20000901
			US 2000-230601P	P 20000906
			WO 2001-JP7438	W 20010829
			US 2001-943712	B1 20010831

AB Disclosed are medicinal compns. for administering N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmacol. acceptable salt and an HMG-CoA reductase inhibitor either at the same time or sep. after a definite period of time. Blood lipid-lowering effect of oral administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate (I) 30 and pravastatin 3 mg/kg in hamsters was examined. Also, tablet containing I 30, sodium pravastatin 10, lactose 408, corn starch 50, and magnesium stearate 2 mg was formulated.

IT 189198-32-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

PROV antihypert.

IA by  
7 yr

has end  
compd.

own  
IA/  
2/1/02

(medicinal compns. for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and HMG-CoA reductase inhibitors)


RN 189198-32-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9


CMF C25 H40 N2 O3



CM 2

CRN 7664-93-9

CMF H2 O4 S




IT 189198-30-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(medicinal compns. for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and HMG-CoA reductase inhibitors)

RN 189198-30-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



Yes

**REFERENCE COUNT:**

17

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:113163 CAPLUS

DOCUMENT NUMBER: 136:167280

TITLE: Preparation of 5-carboxymethylindolines

INVENTOR(S): Kamiya, Shoji; Matsui, Hiroshi

PATENT ASSIGNEE(S): Kyoto Pharmaceutical Industries, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

Patent

Japanese

1

DOCUMENT TYPE:

LANGUAGE:


FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.  
-----  
JP 2002047269

PRIORITY APPLN. INFO.:  
OTHER SOURCE(S):  
GI

KIND	DATE	APPLICATION NO.	DATE
A2	20020212	JP 2000-233250 JP 2000-233250	20000801 20000801
CASREACT 136:167280; MARPAT 136:167280			



AB The compds. I (Y = CO<sub>2</sub>H; R1 = alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, etc.; R2, R3, R5 = H, lower alkyl, lower alkoxy; R4 = alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, etc.; A = alkylene; Z = CH<sub>2</sub>CH<sub>2</sub>, CH:CH) or their salts, as ACAT and lipid peroxidn. inhibitors, are prepared by carbamoylation of cyano compds. I (Y = cyano; R1 = protecting group; R2, R3, R5, A, Z = same as above), reaction of I (Y = CONH<sub>2</sub>; R1 = H; R2, R3, R5, A, Z = same as above) or their salts with R1X (R1 = same as above; X = leaving group), and carboxylation of I (Y = CONH<sub>2</sub>; R1 = alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, etc.; R2, R3, R5, A, Z = same as above) or their salts. N-(1-acetyl-5-cyanomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide was treated with NaOH in MeOH under reflux for 20 h and alkylated with n-octyl bromide in DMF in the presence of K<sub>2</sub>CO<sub>3</sub> and KI at 40° for 24 h to give N-(5-carbamoylmethyl-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide, which was treated with NaOH in PrOH at 90-100° for 12 h to give 98% N-(5-carboxymethyl-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide sulfate.

IT 189198-32-1P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of carboxymethylindolines)

RN 189198-32-1 CAPLUS


CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9

CMF C25 H40 N2 O3


*different, inventor  
as signed*



Yes

CM 2

CRN 7664-93-9  
CMF H2 O4 S



L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1997:326877 CAPLUS  
 DOCUMENT NUMBER: 126:305540  
 TITLE: Preparation of benzene-fused heterocyclic derivatives as inhibitors of acyl-coenzyme A:cholesterol acyltransferase (ACAT) and medicinal use thereof  
 INVENTOR(S): Kamiya, Shoji; Shirahase, Hiroaki; Matsui, Hiroshi; Nakamura, Shohei; Wada, Katsuo  
 PATENT ASSIGNEE(S): Kyoto Pharmaceutical Industries, Ltd., Japan  
 SOURCE: PCT Int. Appl., 121 pp.

DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9712860	A1	19970410	WO 1996-JP2852	19960930
W: AL AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI				
CA 2233842	AA	19970410	CA 1996-2233842	19960930
AU 9670977	A1	19970428	AU 1996-70977	19960930
AU 708571	B2	19990805		
EP 866059	A1	19980923	EP 1996-932060	19960930
EP 866059	B1	20011205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1203587	A	19981230	CN 1996-198670	19960930
CN 1097043	B	20021225		
BR 9610846	A	19990713	BR 1996-10846	19960930

OM  
14/49

JP 2968050	B2	19991025	JP 1996-514152	19960930
RU 2173316	C2	20010910	RU 1998-108605	19960930
IL 123939	A1	20011125	IL 1996-123939	19960930
AT 210116	E	20011215	AT 1996-932060	19960930
ES 2164920	T3	20020301	ES 1996-932060	19960930
PT 866059	T	20020328	PT 1996-932060	19960930
CZ 292632	B6	20031112	CZ 1998-996	19960930
TW 429250	B	20010411	TW 1996-85112125	19961004
NO 9801485	A	19980602	NO 1998-1485	19980401
US 6063806	<i>circled</i> Spec	20000516	US 1998-51202	19980403
HK 1015781	A1	20030822	HK 1999-100913	19990305
US 6200988	B1	20010313	US 2000-506839	20000218
CN 1361100	A	20020731	CN 2001-142957	20011130
			JP 1995-259082	A 19951005
			JP 1996-58018	A 19960314
			JP 1996-194331	A 19960724
			WO 1996-JP2852	W 19960930

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 126:305540  
GI



AB Heterocyclic derivs. represented by general formula (I; one of R1, R2, and R5 = OH, CO<sub>2</sub>H, alkoxy carbonyl, NR<sub>9</sub>R<sub>10</sub>, or alkyl or alkenyl substituted by OH, acidic group, or NR<sub>9</sub>R<sub>10</sub> and the others = H, lower alkyl or alkoxy; wherein R<sub>9</sub>, R<sub>10</sub> = H, lower alkyl; one of R<sub>3</sub> and R<sub>4</sub> = NHCOR<sub>7</sub> and the other = H, lower alkyl or alkoxy; wherein R<sub>7</sub> = alkyl, alkoxy alkyl, alkylthio alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, NHR<sub>8</sub>; wherein R<sub>8</sub> = alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl; R<sub>6</sub> = alkyl, alkenyl, alkoxy alkyl, alkylthio alkyl, cycloalkyl, cycloalkylalkyl, arylalkyl; Z = a linkage group required to form a 5- to 6-membered ring together with NR<sub>6</sub> and C atoms of the benzene ring) or pharmaceutically acceptable salts thereof are prepared. The compds. or pharmaceutically acceptable salts thereof show excellent effects of inhibiting ACAT and inhibiting the peroxidn. of lipids on mammals and thus are useful as ACAT inhibitors and lipid peroxidn. inhibitors. Namely, they are useful in the prevention and treatment of, for example, arteriosclerosis, hyperlipemia, arteriosclerotic lesions in association with diabetes, and ischemic diseases in brain and heart. Thus, N-(1-acetyl-5-chloromethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide was heated with AcOK in MeCN/DMF at 60° under stirring for 1 h, followed by saponification with NaOH in aqueous EtOH under reflux, to give N-(5-hydroxymethyl-4,6-dimethylindolyl-7-yl)-2,2-dimethylpropanamide, which was alkylated by 1-iodooctane in the presence of K<sub>2</sub>CO<sub>3</sub> in DMF to give at 50° for 2 h N-(1-octyl-5-hydroxymethyl-4,6-dimethylindolyl-7-yl)-2,2-dimethylpropanamide (II). II in vitro inhibited by 99.2% the production of cholestryol oleate from [1-14C]oleoyl CoA in microsome fraction of rabbit small intestinal membrane and at 10 mg/kg per day for 3 days in vivo lowered by 57.1% a total serum cholesterol in rats fed with a high cholesterol diet.


IT 189198-30-9P 189198-31-0P 189198-32-1P  
189198-33-2P 189198-34-3P 189198-49-0P

189198-55-8P 189198-58-1P 189198-59-2P  
 189198-60-5P 189198-61-6P 189198-62-7P  
 189198-63-8P 189198-64-9P 189198-65-0P  
 189198-66-1P 189198-68-3P 189198-69-4P  
 189198-71-8P 189198-72-9P 189198-74-1P  
 189198-75-2P 189198-77-4P 189198-78-5P  
 189198-79-6P 189198-80-9P 189198-82-1P  
 189198-83-2P 189198-84-3P 189198-85-4P  
 189198-95-6P 189198-96-7P 189198-97-8P  
 189198-98-9P 189199-33-5P 189199-34-6P  
 189199-36-8P 189199-38-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of benzene-fused heterocyclic derivs. as inhibitor of acyl-CoA:cholesterol acyltransferase and lipid peroxidn. for disease therapy)


RN 189198-30-9 CAPPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



RN 189198-31-0 CAPPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 189198-32-1 CAPPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 189198-30-9

CMF C25 H40 N2 O3



CM 2


CRN 7664-93-9  
CMF H<sub>2</sub> O<sub>4</sub> S



RN 189198-33-2 CAPLUS  
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, mononitrate (9CI) (CA INDEX NAME)


CM 1

CRN 189198-30-9  
CMF C<sub>25</sub> H<sub>40</sub> N<sub>2</sub> O<sub>3</sub>




CM 2

CRN 7697-37-2  
CMF H N O<sub>3</sub>



RN 189198-34-3 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, monosodium salt (9CI) (CA INDEX NAME)




yes

● Na

RN 189198-49-0 CAPLUS


CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)



homology


RN 189198-55-8 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(6-methylheptyl)- (9CI) (CA INDEX NAME)




RN 189198-58-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-nonyl- (9CI) (CA INDEX NAME)





RN 189198-59-2 CAPLUS  
 CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(7-methyloctyl)- (9CI) (CA INDEX NAME)




homolog (isomer)

RN 189198-60-5 CAPLUS  
 CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-(5-ethylheptyl)-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-61-6 CAPLUS  
 CN 1H-Indole-5-acetic acid, 1-decyl-7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-62-7 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(8-methylnonyl)- (9CI) (CA INDEX NAME)




RN 189198-63-8 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-undecyl- (9CI) (CA INDEX NAME)




RN 189198-64-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(9-methyldecyl)- (9CI) (CA INDEX NAME)




RN 189198-65-0 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[ (2,2-dimethyl-1-oxopropyl)amino]-1-dodecyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-66-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(10-methylundecyl)- (9CI) (CA INDEX NAME)




RN 189198-68-3 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxohexyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-69-4 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxohexyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-71-8 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxooctyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-72-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxooctyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-74-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxodecyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 189198-75-2 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxodecyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-77-4 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-4,6-diethyl-1-heptyl-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 189198-78-5 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-4,6-diethyl-2,3-dihydro-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-79-6 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-4,6-diethyl-2,3-dihydro-1-nonyl- (9CI) (CA INDEX NAME)




RN 189198-80-9 CAPLUS

CN 1H-Indole-5-acetic acid, 1-decyl-7-[(2,2-dimethyl-1-oxopropyl)amino]-4,6-diethyl-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 189198-82-1 CAPLUS


CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 189198-83-2 CAPLUS  
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethoxy-1-octyl- (9CI) (CA INDEX NAME)




RN 189198-84-3 CAPLUS  
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethoxy-1-nonyl- (9CI) (CA INDEX NAME)



RN 189198-85-4 CAPLUS  
CN 1H-Indole-5-acetic acid, 1-decyl-7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 189198-95-6 CAPLUS  
CN 1H-Indole-5-acetic acid, 1-heptyl-2,3-dihydro-6-methyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)




RN 189198-96-7 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-6-methyl-1-octyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)




RN 189198-97-8 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-6-methyl-1-nonyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)




RN 189198-98-9 CAPLUS

CN 1H-Indole-5-acetic acid, 1-decyl-2,3-dihydro-6-methyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)




RN 189199-33-5 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-7-[(3-methoxy-1-oxopropyl)amino]-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)




RN 189199-34-6 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-4,6-dimethyl-7-[(3-(methylthio)-1-oxopropyl)amino]-1-octyl- (9CI) (CA INDEX NAME)




RN 189199-36-8 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(cyclohexylacetyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



RN 189199-38-0 CAPLUS

CN 1H-Indole-5-acetic acid, 2,3-dihydro-4,6-dimethyl-1-octyl-7-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

FULL ESTIMATED COST

44.91 206.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

CA SUBSCRIBER PRICE

-6.57 -6.57

STN INTERNATIONAL LOGOFF AT 14:02:27 ON 25 FEB 2005